NCT05925504View on ClinicalTrials.gov

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Lower Risk MDS Per IPSS-R
Interventions
DRUG

Luspatercept

The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.

Trial Locations (1)

300131

RECRUITING

Regenerative Medicine Center, Tianjin

All Listed Sponsors
collaborator

Beijing Health Alliance Charitable Foundation

UNKNOWN

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER